Modular Medical, Inc.
A filing-based review of operating performance, liquidity, equity financing, material corporate developments and documented capital-market events.
1. Business and financial performance
The company’s patch-pump strategy has a potentially identifiable commercial market, but manufacturing scale, reimbursement, adoption and gross margins must support the spending required to reach it.
Modular Medical’s June 30, 2026 Form 10-Q reported approximately $6.5 million in net loss for the quarter and $3.9 million in cash and cash equivalents at quarter end. It disclosed substantial doubt about its ability to continue as a going concern.
2. Liquidity and going concern
A separate, filing-supported assessment of liquidity and going-concern status is not established in this edition.
3. Equity financing and dilution
The loss and cash figures are from different measures and should not be divided mechanically to claim a precise runway. Timing of payments, working capital and new financing can change liquidity.
4. Exchange listing and trading events
No exchange-listing or trading event has been established from the source material included in this edition.
5. Strategic developments and corporate actions
The company’s patch-pump strategy has a potentially identifiable commercial market, but manufacturing scale, reimbursement, adoption and gross margins must support the spending required to reach it.
Primary document: Review underlying regulatory source ↗
6. Evidence ledger
7. Research conclusion
The evidence included in this edition is insufficient for a directional investment conclusion.
Independent research and non-compensation disclosure
Unsolicited, non-sponsored proprietary research. AnalystPitch.com independently selected Modular Medical, Inc. as the subject of this report and initiated its preparation and publication on its own initiative. Modular Medical, Inc. did not request, commission, sponsor, direct, or authorize this publication and had no involvement in the research process, editorial decisions, or approval of the report.
Compensation received or promised for this publication: US$0.00. AnalystPitch.com states that it has received no cash, securities, warrants, options, expense reimbursement, or other direct or indirect consideration from Modular Medical, Inc. or anyone acting on its behalf in exchange for preparing, publishing, or distributing this report, and that no such consideration has been promised. This report is not paid securities promotion or issuer-sponsored research.
Section 17(b) transparency. Section 17(b) of the Securities Act of 1933 addresses certain securities publicity published for consideration received directly or indirectly from an issuer, underwriter, or dealer. The compensation statement above describes the circumstances of this report; it is not a claim that the SEC has reviewed, approved, or certified the report or this disclosure.
Other potential conflicts. The absence of payment for this publication does not by itself establish the absence of other financial interests or relationships. Any material securities holdings, financing arrangements, advisory engagements, or other relevant conflicts involving the publisher or its responsible contributors should be separately disclosed where applicable.
This publication is informational research, not personalized investment advice, an offer to sell securities, or a solicitation to purchase securities.
9. Primary documents
Primary referenced regulatory filing or source ↗
SEC EDGAR — search subsequent company filings ↗
Information cutoff: 13 October 2026. Not all financial line items have been independently recalculated. This report does not purport to reproduce a full audited financial model. Information can become outdated after the cutoff.